US20180289751A1 - Antimicrobial therapy - Google Patents

Antimicrobial therapy Download PDF

Info

Publication number
US20180289751A1
US20180289751A1 US15/570,272 US201615570272A US2018289751A1 US 20180289751 A1 US20180289751 A1 US 20180289751A1 US 201615570272 A US201615570272 A US 201615570272A US 2018289751 A1 US2018289751 A1 US 2018289751A1
Authority
US
United States
Prior art keywords
peptide
strain
staphylococcus
antimicrobial
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/570,272
Other languages
English (en)
Inventor
Teruaki Nakatsuji
Richard L. Gallo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Priority to US15/570,272 priority Critical patent/US20180289751A1/en
Publication of US20180289751A1 publication Critical patent/US20180289751A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF CALIFORNIA, SAN DIEGO
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA reassignment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GALLO, RICHARD L., NAKATSUJI, Teruaki
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Definitions

  • the disclosure relates to methods and compositions for treating infection, and modulating skin and mucosal microflora to treat diseases or disorders that are related to or exacerbated by dysbiosis.
  • AMPs Small, cationic antimicrobial peptides
  • AMPs are naturally occurring antibiotics of the innate immune system.
  • Their spectrum of activity includes Gram-positive and Gram-negative bacteria as well as fungi and certain infective agents.
  • researchers are exploring these endogenous antibiotics as a potential source or new therapies against variety of infectious diseases.
  • SA Staphylococcus aureus
  • AMPs antimicrobial peptides
  • Symptoms of atopic dermatitis also referred to as eczema or atopic eczema include: dry skin that forms a rash; scaly, swollen, and red skin; rash on the face, or inside the knees, elbows, or wrists; blisters that ooze; changes in skin color after repeated episodes; thickened, cracked, dry, scaly skin or skin that looks leathery in patches; and severe itchiness (pruritis), especially at night, along with raw, sensitive, swollen skin from scratching.
  • Atopic dermatitis signs and symptoms vary widely from person to person and may further include: red to brownish-gray patches, especially on the hands, feet, ankles, wrists, neck, upper chest, eyelids, inside the bend of the elbows and knees, and, in infants, the face, scalp, back of the head, ears, legs, feet, arms, hands and buttocks; small, raised bumps, which may leak fluid and crust over when scratched.
  • Atopic dermatitis most often begins before age 5 and may persist into adolescence and adulthood. For some people, it flares periodically and then clears up for a time, even for several years.
  • the skin changes brought about by atopic dermatitis can facilitate high susceptibility of these patients to colonization and infections by Staphylococcus aureus.
  • Dysbiosis comprises an imbalance in the cutaneous or mucosal flora, including the nasal, oral, ophthalmic, urogenital, intestinal flora, wherein species such as S. aureus become overrepresented and other species become underrepresented.
  • nonpathogenic bacteria may secrete inhibitors or simply occupy all available niches, thus either directly inhibiting or indirectly excluding pathogens that would otherwise be able to establish infectious states or foster the development of disease or disease-like states, such as atopic dermatitis.
  • compositions and methods for the treatment of disorders related to dysbiosis of the skin are provided. These disorders, associated with imbalances in the normal skin flora and overgrowth of skin pathogens such as S. aureus , result in skin infections, atopic dermatitis, and psoriasis, among other conditions.
  • compositions and methods for treating these disorders by restoring the healthy cutaneous flora utilizing antimicrobial peptides derived from residents of the healthy cutaneous flora, or by directly administering probiotic compositions containing strains that are derived from a healthy cutaneous flora, or as the rare surviving florae cultured from the skin of diagnosed patients with a floral dysbiosis, and that are capable of either killing or inhibiting the growth of pathogenic species on the skin or species associated with a disease-like microbial imbalance.
  • the disclosure provides a thickened topical composition
  • a thickened topical composition comprising one or more probiotic bacterial strains, preferably of the genus Staphylococcus , and more preferably comprising the disclosed strains of Staphylococcus hominis and Staphylococcus epidermidis .
  • These strains can be isolated from healthy cutaneous florae, or as the surviving florae cultured from the skin of diagnosed patients with a floral dysbiosis, by the methods disclosed herein, and may be identified by the secreted peptide sequences, fatty acid methyl ester profiles, and/or antimicrobial peptide codon organizations disclosed herein.
  • the probiotic strains of the disclosure may be provided in live form, in freeze-dried form, or in a reconstitutable form.
  • the disclosure further provides a composition comprising strains of Staphylococcus epidermidis and Staphylococcus hominis as described herein which may be formulated for topical administration to the skin, scalp, or mucosae.
  • the disclosure further provides a composition wherein the probiotic bacterial strains comprise one or more of S.
  • epidermidis strains Staphylococcus epidermidis strains M034, M038, A11, AMT1, AMT5-C5, and/or AMT5-G6 and/or Staphylococcus hominis strains A9, C2, AMT2, AMT3, AMT4-C2, AMT4-G1, and/or AMT4-D12.
  • compositions of the disclosure may also comprise conditioned culture medium, or isolated antimicrobial compounds derived from the strains described herein, such as the peptides designated here as Hogocidins.
  • the disclosure contemplates the use of heterologously expressed or synthetic hogocidins, hogocidin derivatives, or hogocidin-like peptides.
  • the disclosure also provides a composition comprising a hogocidin peptide, derivative or variant and a cathelicidin peptide, derivative or variant.
  • the disclosure further provides a composition of any of the foregoing embodiments, wherein the peptide comprises one or more D-amino acids, one or more non-naturally occurring amino acids, and/or one or more post-translational modifications.
  • the disclosure provides a composition of any of the foregoing embodiments, wherein the peptide is substantially purified from other peptides.
  • the disclosure provides a composition of any of the foregoing embodiments, wherein the peptide is partially purified from other peptides.
  • the disclosure provides a composition wherein the peptide is present in a crude extract.
  • the disclosure provides a composition of any of the foregoing embodiments in a formulation for topical administration.
  • compositions of any of the foregoing embodiments, wherein the formulation comprises a lotion, ointment or spray or cream or oil suspension, but not limited to these formats.
  • the hogocidin peptide, derivative or variant comprises a sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:2 or 4 comprising a non-natural amino acid, SEQ ID NO:2 or 4 comprising a D-amino acid, or SEQ ID NO:2 or 4 comprising a fusion construct.
  • the disclosure also provides a method for inhibiting the spread and/or reducing the risk of infection with a microbe comprising contacting the microbe with an effective amount of a composition of the disclosure.
  • the contacting is in vivo.
  • the contacting in vivo is by topical administration.
  • the disclosure further provides a method of treating skin or mucosal infections, atopic dermatitis, psoriasis, acne, or other disorders related to skin dysbiosis by applying to the skin or mucosa an effective amount of the compositions disclosed herein to a subject in need thereof.
  • the disclosure provides a method of treating atopic dermatitis comprising contacting a subject having or suspected of having atopic dermatitis with an effective amount of a probiotic composition comprising one or more of the bacterial strains disclosed herein.
  • the disclosure provides a method of treating atopic dermatitis comprising contacting a subject having or suspected of having atopic dermatitis with an effective amount of a hogocidin peptide, derivative or variant.
  • the disclosure provides a method of treating atopic dermatitis or dysbiosis of the skin by contacting the affected area with a composition comprising bacterial strains that secrete hogocidin, firmocidin, SH-lantibiotic peptide, SH-antimicrobial, SE-lantibiotic peptide, or SE antimicrobial such as Staphylococcus hominis strain A9, Staphylococcus hominis strain C2, Staphylococcus hominis strain AMT2, Staphylococcus hominis strain AMT3, Staphylococcus hominis strain AMT4-C2, Staphylococcus hominis strain AMT4-G1, Staphylococcus hominis strain AMT4-D12, Staphylococcus epidermidis strain AMT1, Staphylococcus epidermidis strain SE-A11 , Staphylococcus epidermidis strain AMT5-C5, and Staphylococcus epidermidis strain AMT5-G6.
  • the disclosure
  • the disclosure provides a composition
  • a composition comprising a thickened topical formulation of one or more probiotic bacterial strains and optionally, a prebiotic compound, a protectant, humectant, emollient, abrasive, salt, and/or surfactant; wherein the one or more probiotic bacterial strain comprises one or more bacterial strains of the genus Staphylococcus ; and wherein the composition is formulated for the topical treatment of disorders of dysbiosis of the skin, scalp, or mucosae.
  • the one or more probiotic bacterial strain comprises Staphylococcus epidermidis, Staphylococcus hominis or a combination of Staphylococcus epidermidis and Staphylococcus hominis .
  • the one or more probiotic bacterial strain comprises Staphylococcus epidermidis strains MO34, MO38, A11, AMT1, AMT5-C5, and/or AMT5-G6.
  • one or more probiotic bacterial strains comprises Staphylococcus hominis strains A9, C2, AMT2, AMT3, AMT4-C2, AMT4-G1, and/or AMT4-D12.
  • each probiotic bacterial strain demonstrates a Fatty Acid Methyl Ester profile corresponding to one of those shown in any of FIG. 11, 12, 13, 14, 15, 16, 17, 18 , or 19 .
  • the one or more probiotic bacterial strains produces a peptide having a sequence selected from the group consisting of SEQ ID NO: 2, 4, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, and 55 and any combination thereof and wherein such peptide is optionally post-translationally modified.
  • the one or more probiotic bacterial strains is provided in a live form.
  • the one or more probiotic bacterial strains is provided in a lyophilized or freeze-dried or spray dried form.
  • the probiotic bacterium can be reconstituted into a live form.
  • the disclosure also provides a method of treating skin or mucosal infections, atopic dermatitis, psoriasis, mastitis, acne, or other disorders related to skin dysbiosis in humans or other mammals by applying to the skin or mucosa an effective amount of a composition as described herein and in the preceding paragraph.
  • the composition is applied topically.
  • the composition is formulated as a cream, ointment, unguent, spray, powder, oil, thickened formulation or poultice.
  • the disclosure also provides a composition comprising one or more of a hogocidin peptide, derivative or variant, an SH-lantibiotic peptide, an SH-antimicrobial, an SE-lantibiotic peptide, and/or an SE antimicrobial; and further comprising one or more thickeners, solvents, emulsifiers, or pharmaceutically acceptable carriers or excipients.
  • the composition further comprises a cathelicidin peptide, derivative or variant.
  • the hogocidin peptide, derivative or variant, the SH-lantibiotic peptide, and/or the SE-lantibiotic peptide comprises one or more D-amino acids or non-naturally occurring amino acids.
  • the hogocidin peptide, SH-lantibiotic peptide, SH-antimicrobial, SE-lantibiotic peptide, or SE antimicrobial is produced in situ by one or more of Staphylococcus hominis strain A9, Staphylococcus hominis strain C2, Staphylococcus hominis strain AMT2, Staphylococcus hominis strain AMT3, Staphylococcus hominis strain AMT4-C2, Staphylococcus hominis strain AMT4-G1, Staphylococcus hominis strain AMT4-D12, Staphylococcus epidermidis strain AMT1, Staphylococcus epidermidis strain SE-A11 , Staphylococcus epidermidis strain AMT5-C5, Staphylococcus epidermidis strain AMT5-G6 and Staphylococcus epidermidis strain M034.
  • the one or more of a hogocidin peptide, derivative or variant, an SH-lantibiotic peptide, an SH-antimicrobial, an SE-lantibiotic peptide, an SE antimicrobial, and a cathelicidin peptide, derivative or variant is provided as an extract or lysate of Staphylococcus hominis strain A9, Staphylococcus hominis strain C2, Staphylococcus hominis strain AMT2, Staphylococcus hominis strain AMT3, Staphylococcus hominis strain AMT4-C2, Staphylococcus hominis strain AMT4-G1, Staphylococcus hominis strain AMT4-D12, Staphylococcus epidermidis strain AMT1, Staphylococcus epidermidis strain SE-A11 , Staphylococcus epidermidis strain AMT5-C5, Staphylococcus epidermidis strain AMT5-G6 and Staphylococcus epi
  • the disclosure also provides a method for treating skin or mucosal infection or atopic dermatitis in a subject comprising contacting the subject with an effective amount of a composition comprising one or more of a hogocidin peptide, derivative or variant, an SH-lantibiotic peptide, an SH-antimicrobial, an SE-lantibiotic peptide, and optionally, a cathelicidin peptide, derivative or variant.
  • the contacting is by topical administration or optionally by contacting the subject with one or more of SH-lantibiotic or bacteriocin-producing Staphylococcus hominis strains A9, C2, AMT2, AMT3, AMT4-C2, AMT4-G1, AMT4-D12 and Staphylococcus epidermidis strains AMT5-G6 and M034.
  • the disclosure also provides a recombinant vector comprising a polynucleotide encoding a polypeptide that is at least 95% identical to SEQ ID NO:2 or 4, or a biologically active fragment thereof having antimicrobial activity.
  • the vector comprises a polynucleotide that encodes a polypeptide of SEQ ID NO:2 or 4. In yet another embodiment, the vector comprises a polynucleotides that encodes a polypeptide of SEQ ID NO:2 from about amino acid 32 to about amino acid 61. In a further embodiment, the vector comprises a polynucleotide that encodes a polypeptide of SEQ ID NO:4 from about amino acid 29 to about amino acid 66. In another embodiment, the vector comprises a polynucleotide that is at least 95% identical to SEQ ID NO:1 or 3 and encodes a polypeptide of SEQ ID NO:2 or 4, respectively. In yet another embodiment of the foregoing embodiments, the vector comprises a fragment of SEQ ID NO:1 or 3. In yet a further embodiment of any of the foregoing, the vector is an expression vector.
  • the disclosure also provides a host cell engineered to express a recombinant vector of the disclosure.
  • the host cell is a non-pathogenic attenuated host cell.
  • the disclosure also provide a recombinant polypeptide produced by the host cell of the disclosure.
  • the recombinant polypeptide is purified from a host cell culture.
  • the disclosure also provides a composition comprising the host cell of disclosure.
  • FIG. 1A-D The ratio of culturable Staphylococcus compared to Staphylococcus DNA is higher in lesional skin of atopic dermatitis.
  • FIG. 1A Culturable total Staphylococcus spp. were counted on a selective mannitol salt agar plate from 49 subjects with atopic dermatitis (AD) and 30 subjects without AD.
  • FIG. 1B CFU results for growth of S. aureus are shown from 30 non-atopic subjects and 49 atopic dermatitis patients.
  • FIG. 1C Total Staphylococcus spp. DNA abundance was determined by quantitative PCR (qPCR) on DNA from 14 non-atopic and 37 atopic subjects.
  • Relative CFU was determined by comparison to a standard of known CFUs of S. epidermidis (ATCC12228).
  • FIG. 1D The ratio of live Staphylococcus spp. CFU to relative abundance of Staphylococcus determined by DNA was calculated at each corresponding skin site.
  • FIG. 2A-C Atopic dermatitis skin is colonized by coagulase-negative Staphylococcus with a low frequency of antimicrobial activity.
  • FIG. 2A Coagulase-negative Staphylococcus (CONS) with antimicrobial activity against S. aureus was determined by a high-throughput assay of individual culture isolates and the proportion (%) of total colonies that inhibited growth of S. aureus was determined.
  • FIG. 2B The proportion of CoNS with antimicrobial activity was determined from the same subjects at day-1, day-7 and day-14.
  • FIG. 2C The ratio of live Staphylococcus spp. to abundance of Staphylococcus DNA was determined from the same subjects as in FIG. 2B . *P ⁇ 0.05, ****P ⁇ 0.0001. 11 atopic and 11 non atopic subjects were randomly selected for analysis in Panels B and C.
  • FIG. 3A-B Antimicrobial coagulase-negative Staphylococcus correlate with the absence of S. aureus colonization.
  • FIG. 3A The proportion of antimicrobial CoNS in each sample is plotted against the abundance of S. aureus cultured from each subject. Quadrants are divided based on frequency of antimicrobial CoNS (>50% or ⁇ 50%) and detection of live S. aureus ( ⁇ 1 CFU/cm 2 or >1 CFU/cm 2 ). The proportion (%) of subjects in each quadrant to total subjects is shown.
  • FIG. 3B The frequency of antimicrobial CoNS in S. aureus -culture negative subjects (white) and S. aureus -culture positive subjects (solid) are shown. Data are mean ⁇ SE for 29 non-atopic subjects and 41 nonlesional or 40 lesional sites of atopic subjects.
  • FIG. 4A-B Diverse bacterial species have antimicrobial activity. Species of antimicrobial or non-antimicrobial CoNS were identified by DNA sequencing of full length 16S rRNA from randomly isolated colonies with and without antimicrobial activity. FIG. 4A : Proportions of CoNS species identified with antimicrobial activity from 5 non-atopic subjects. FIG. 4B : Proportions of CoNS species identified from antimicrobial and non-antimicrobial colonies isolated from subjects with atopic dermatitis. Up to 48 CoNS isolates were sequenced from each individual. The relative proportion of colonies with antimicrobial (solid) and non-antimicrobial CoNS (white) from each AD subject is shown by pie chart.
  • FIG. 5A-B Identification of antimicrobial peptides from a coagulase-negative Staphylococcus strain within the skin microbiome (SH-A9).
  • FIG. 5A Amino acid sequence and predicted mono and di-sulfide bonds from two antimicrobial peptides purified from S. hominis isolated from non-atopic skin. Peptides are named Hogocidin- ⁇ (SEQ ID NO:2 from aa 32-61) and Hogocidin- ⁇ (SEQ ID NO:4 aa 29-66) (SH-lantibiotic ⁇ and ⁇ ).
  • FIG. 5B shows dose response curves for the antimicrobial activity of Hogocidin- ⁇ and Hogocidin- ⁇ against S. aureus .
  • Co-incubation with an antimicrobial peptide produced by human skin (LL-37) shows synergistic activity.
  • Data represent mean ⁇ SE of triplicate assays.
  • Arrow shows minimal inhibitory concentration (MIC) of each AMP, defined as 3-log reduction of viable bacteria in comparison to control.
  • Dha 2,3-didehydroalanine
  • Dhb 2,3-didehydroalanine
  • FIG. 6 Abundance of S. aureus DNA on non-atopic skin, nonlesional and lesional site of atopic skin.
  • Fourteen and 37 DNA swabs were obtained from 30 normal and 50 atopic dermatitis patients recruited, respectively.
  • the abundance of S. aureus DNA was determined by qPCR with species-specific primers targeting the S. aureus -specific femA gene.
  • Relative CFU (rCFU) of S. aureus DNA was determined by comparison with known CFUs of S. aureus (ATCC35556). Density of live bacteria or bacterial DNA was normalized into the area swabbed.
  • AD atopic dermatitis.
  • FIG. 7A-B Purification and mass spectrometric analysis of AMPs produced by S. hominis isolated from non-atopic skin (SH-A9). AMPs were purified by HPLC using CapcelPac C8 column from culture supernatant of a representative antimicrobial isolate of S. hominis ( FIG. 7A ). The last step of 5 purification steps is shown. The insert panel represents antimicrobial activity of each fraction on radial diffusion assay against S. aureus . Fractions with antimicrobial activity were characterized by MALDI-TOF-MS ( FIG. 7B ).
  • FIG. 8 Representation of amino acids losses in genome-guided MALDI-TOF/TOF analysis for Hogocidin- ⁇ (SH-lantibiotic- ⁇ ). Amino acid sequence of purified Hogocidin- ⁇ was obtained from amino acids losses in MS/MS fragmentation spectrum of precursor mass 3547.7 m/z. Dha, 2,3-didehydroalanine; Dhb, (Z)-2,3-didehydrobutyrine.
  • FIG. 9A-B Organization of gene clusters encoding Hogocidin precursors and lantibiotic biosynthetic genes in a S. hominis strain isolated from non-atopic skin (SH-A9).
  • FIG. 9A shows the order of lantibiotic precursors (A1 and A2; SH-lantibiotic- ⁇ and ⁇ ) and biosynthetic genes (C, T and M) on the S. hominis SH-A9 genome.
  • FIG. 9B lists hypothetical gene, gene locus and putative function. This S. hominis strain contains multiple copies of the lantibiotic-related gene clusters.
  • FIG. 10 shows the high-throughput methodology used in the disclosure.
  • FIG. 11A-B Chromatograms showing results of FAME analysis of S. epidermidis strains MO-34 and MO-38, which were identified by the methods given in the present disclosure.
  • FIG. 12A-B Chromatograms showing results of FAME analysis of S. hominis strains A9 and C2, which were identified by the methods given in the present disclosure.
  • FIG. 13A-B Chromatograms showing results of FAME analysis of S. epidermidis strains A11 and AMT1-A9, which were identified by the methods given in the present disclosure.
  • FIG. 14A-B Chromatograms showing results of FAME analysis of S. hominis strains AMT2-A11 and AMT3-A12, which were identified by the methods given in the present disclosure.
  • FIG. 15A-B Chromatograms showing results of FAME analysis of S. hominis strains AMT4-C2 and AMT4-G1, which were identified by the methods given in the present disclosure.
  • FIG. 16A-B Chromatograms showing results of FAME analysis of S. hominis strains AMT4-D12 and S. epidermidis AMT5-C5, which were identified by the methods given in the present disclosure.
  • FIG. 17A-B Chromatograms showing results of FAME analysis of S. epidermidis strain AMT5-G6, which was identified by the methods given in the present disclosure, and S. hominis strain C4, which does not produce hogocidin.
  • FIG. 18A-B Chromatograms showing results of FAME analysis of S. hominis strains C5 and C6, which do not produce hogocidin.
  • FIG. 19A Chromatogram showing results of FAME analysis of S. epidermidis strain MO1, which does not produce SE-lantibiotics or SE-antimicrobials.
  • FIG. 20A-E Transplantation of antimicrobial CoNS reduces survival of S. aureus on the skin.
  • FIG. 20A Effect of S. hominis on survival of S. aureus on pigskin. Live S. hominis A9 that produces hogocidin (1 ⁇ 10 CFU/cm 2 ) was compared to controls including UV-killed and washed A9 strain, strains of live S. hominis that do not produce AMP activity (C4, C5 and C6) or vehicle cream alone with the pigskin assay. Data represent mean ⁇ s.e.m. of five independent assays.
  • FIG. 20B Effect of bacterial transplantation on survival of S. aureus on mouse skin. S.
  • FIG. 20C Work flow for autologous human microbiome transplant (AMT) on AD subjects colonized with S. aureus .
  • FIG. 20D Characterization of CoNS clones used for AMT. Antimicrobial class of each clone was identified by whole genome sequencing.
  • S. aureus survival was measured by colony counting of swabs taken before transplant (baseline) and 24 hrs after treatment. Difference in S. aureus between vehicle and AMT arms is shown as A % S. aureus CFU. Inactive strains have no effect.
  • FIG. 21A-C Hypothetical antimicrobial genes identified in anti- S. aureus strains AMT1-A9 ( FIG. 21A ), AMT2-A12 ( FIG. 21B ), and AMT3-A12 ( FIG. 21C ) used for autologous microbiome transplant.
  • Whole genome sequence of active CoNS clones were obtained by miSeq and analyzed on the RAST Server (rast.nmpdr.org) to identify antimicrobial class.
  • FIG. 22A-B Hypothetical antimicrobial genes identified in anti- S. aureus strains AMT4-C2 ( FIG. 22A ) and AMT4-G1 ( FIG. 22B ) used for autologous microbiome transplant.
  • Whole genome sequence of active CoNS clones were obtained by miSeq and analyzed on the RAST Server (rast.nmpdr.org) to identify antimicrobial class.
  • FIG. 23A-C Hypothetical antimicrobial genes identified in anti- S. aureus strains AMT4-D12 ( FIG. 23A ), AMT5-C5 ( FIG. 23B ), and AMT5-G6 ( FIG. 23C ) used for autologous microbiome transplant.
  • Whole genome sequence of active CoNS clones were obtained by miSeq and analyzed on the RAST Server (rast.nmpdr.org) to identify antimicrobial class.
  • FIG. 24 shows dose-dependent killing curve of antimicrobial peptide purified from culture supernatant of Staphylococcus epidermidis A11 strain isolated from normal skin.
  • Indicated bacterial species (1 ⁇ 10 5 CFU/mL) were incubated with various concentrations of purified Staphylococcus epidermidis A11 antimicrobial peptide (comprising SEQ ID NO:55) in 50% Muller-Hinton Broth/50% PBS at 37° C. for 24 hrs.
  • Propionibacterium acnes were incubated in 100% Reinforsed-Clostridial Media under an anaerobic condition.
  • S. epiA11 Staphylococcus epidermidis A11 strain; S.
  • FIG. 25A-B shows data related to an antimicrobial peptide purified from culture supernatant of a clinical isolate strain of Staphylococcus epidermidis (A11 strain) by HPLC (A). Active fraction (Fraction 33-34) was analyzed by MALDO-TOF mass to estimate molecular weight of active antimicrobial peptide (B). Observed molecular weight was 3484.90 (m/z). N-terminal sequencing of the peptide is provided in SEQ ID NO:55.
  • Atopic dermatitis is a common, chronic skin disorder characterized by dysfunction of the epidermal barrier and relapsing skin inflammation. The severity of this disease is associated with dysbiosis of the skin microbiome and the high susceptibility of these patients to colonization and infections by Staphylococcus aureus.
  • AMPs antimicrobial peptides
  • AMPs antimicrobial peptides
  • the production of antimicrobial peptides provides direct disinfectant activity against invading pathogens.
  • AMPs such as cathelicidins and ⁇ -defensins
  • the skin of patients with atopic dermatitis has a decreased capacity to produce certain AMPs and this is associated with an increased rate of infection by S. aureus , a pathogen that should be killed by these AMPs.
  • S. aureus further exacerbates symptoms of atopic dermatitis and leads to immune dysfunction such as TH2 lymphocyte skewing, reduced AMPs, exacerbated allergic reactions and disruption of the skin barrier.
  • microbiome may produce its own AMPs that could synergize with AMPs produced by host cells. Therefore, in addition to the deleterious effects of colonization by S. aureus , dysbiosis of the microbiome in atopic dermatitis could contribute to disease by loss of their beneficial functions.
  • Existing antibiotic therapies non-specifically kill bacteria, which impacts the homeostasis of the resident microflora.
  • Imbalanced microflora contribute to the pathogenesis of skin inflammatory diseases, such as atopic dermatitis, rosacea and acne vulgaris etc.
  • This disclosure provides compositions and formulations for disinfecting surfaces or treating infections but does not pose the safety risks of non-specific antibiotics. Further the disclosure provides for probiotic approaches wherein subjects may be provided with live S. hominis or S. epidermidis strains which may produce the necessary antimicrobial compounds in situ while simultaneously restoring the characteristics of a healthy cutaneous flora.
  • Staphylococcus hominis ( S. hominis ) is a major constituent of the microflora of healthy human skin.
  • S. epidermidis protect human skin by preventing pathogenic infections by producing phenol-soluble modulins (PSMs) and small molecule antibiotic, named “Firmocidin”, which function as additional antimicrobial compounds on normal human skin (see, e.g., U.S. Pat. Publ. No. 2013/0331384A1, the disclosure of which is incorporated herein by reference).
  • lipoteichoic acid produced by S. epidermidis benefits human skin by suppressing skin inflammation during wound repair.
  • the present disclosure provides the use of live S. epidermidis and/or S. hominis cells or cultures to restore or enhance the normal cutaneous flora to support wound healing and prevent infection and restore skin barrier function.
  • a limitation of DNA sequencing is that it is unable to distinguish between viable and dead organisms, in the methods of the disclosure microbial abundance was directly evaluated in atopic and non-atopic subjects by both culture and DNA quantification techniques.
  • the relative capacity to culture live bacteria compared to measurements of DNA differed greatly between non-atopic and atopic dermatitis patients.
  • Approximately 10 times more bacterial DNA relative to CFUs of cultured bacteria was detected in non-atopic skin compared to atopic lesional skin.
  • AMPs such as LL-37 and hBDs-2 and -3 have lower levels of expression in inflamed skin of atopic patients than inflamed skin of normal subjects, but these AMP expressions are low in non-inflamed skin. Therefore, the increased capacity of the non-inflamed normal skin to kill bacteria is not likely due to the expression of these host AMPs.
  • the high frequency of antimicrobial CoNS observed on non-atopic skin suggests that these resident bacteria are important to resist colonization by pathogens. Supporting this, S. aureus colonization was only detected in subjects with a low frequency of CoNS strains with antimicrobial activity.
  • CoNS that could inhibit biofilm formation have also been observed in the nasal mucosa and inhibited nasal colonization by S. aureus .
  • the observation of the lack of direct antimicrobial activity derived from the community of bacteria residing on the skin of patients with atopic dermatitis defines a previously unknown defect in the innate defense system of these individuals.
  • 16S rRNA sequencing revealed that antimicrobial activity was detected in diverse strains of CONS, such as S. epidermidis, S. hominis, S. warneri , and S. capitis .
  • CONS such as S. epidermidis, S. hominis, S. warneri , and S. capitis .
  • Two prokaryotic AMPs with molecular weights of 3152.2 Da and 3550.7 Da were identified using HPLC, protein sequencing by MALDI-TOF-MS2 and genome sequencing. Additionally, as shown in Nakatsuji, T. et al. (2016), Nature Medicine Submitted Manuscript No. NMED-A78395A, submitted Mar.
  • This discovery illustrates the potential in further analysis of the host-defense function of the healthy human skin microbiome and may provide a genetic approach to predicting the activity of the microbiome. Metagenomic sequencing and correlation with functional screening of the microbiome could be of great benefit in the treatment of patients with atopic dermatitis and other skin diseases.
  • the disclosure provides evidence that the community of bacteria residing on normal human skin provides an important shield against S. aureus .
  • dysfunction in this microbiome-mediated antimicrobial defense system may enable colonization of the skin by S. aureus in atopic dermatitis and further exacerbation of the disease.
  • strategies of bacteriotherapy of the skin may be useful as a method to suppress S. aureus without use of pharmaceutically derived antibiotics.
  • the ideal therapeutic approach to atopic dermatitis should include targeting both repair of the intrinsic epidermal barrier and optimizing the immune defense functions provided by the microbiome.
  • the disclosure also describes novel antimicrobial peptides (AMPs) from culture supernatant of a clinical isolate of S. hominis . These AMPs are referred to herein as Hogocidin- ⁇ and Hogocidin- ⁇ . Hogocidins exert antimicrobial and bactericidal activity against Staphylococcus aureus ( S. aureus ), but do not inhibit the growth of commensal bacteria on the skin such as S. epidermidis . Therefore, the disclosure represents provides antibiotics with potent but selective activity against pathogens, and high safety profile as they are found normally in the human skin microbiome, as well as probiotic approaches to treating these conditions.
  • AMPs novel antimicrobial peptides
  • antimicrobial means that the peptide destroys, or inhibits or prevents the growth or proliferation of, a microbe (e.g., a bacterium, fungus, and/or virus).
  • antiviral means that a peptide destroys, or inhibits or prevents the growth or proliferation of a virus or a virus-infected cell.
  • anti-tumor means that a peptide prevents, inhibits the growth of, or destroys, a tumor cell(s).
  • antifungal means that a peptide prevents, destroys, or inhibits the growth of a fungus.
  • probiotic refers to the process of providing live or attenuated microbial cultures, or lysates, lyophiles or extracts of such cultures, in order to supplement or replace elements of a healthy cutaneous or mucosal flora.
  • An attenuated vector for delivery to the skin can be include a virus or bacteria that has been genetically modified to (a) make the vector non-pathogenic, (b) have reduced pathogenicity, (c) be replication defective, or (d) to be non-antigenic. Other attenuation are known in the art. The attenuation is typically performed by knocking out a gene or disrupting a gene coding sequence or expression control element such that the attention of (a)-(c) or (d) is accomplished. Such techniques are known in the art and numerous such attenuated bacterial and viral vectors are known.
  • the “hogocidins” are composed of two distinct domains: an N-terminal “prosequence” domain and the C-terminal domain of the mature hogocidin.
  • the mature hogocidin- ⁇ comprises a sequence of SEQ ID NO:2 from about amino acid 32 to about amino acid 61 (e.g., beginning at about amino acid 30, 31, 32 or 33 of SEQ ID NO:2 and extending to about amino acid 59, 60 or 61 of SEQ ID NO:2).
  • the pre-pro form of hogocidin- ⁇ is about 61 amino acids in length and is post-translationally process to provide the mature form. Based upon the expression system and organism, the mature form may be processed slightly differently depending upon the proteases present.
  • the pre-pro form of hogocidin- ⁇ can be used in the methods, compositions and kits of the disclosure, wherein prior to or after administration the pre-pro form can be processed in vitro or in vivo.
  • polypeptide comprising SEQ ID NO:2 is typically cleaved following amino acid number 31 of SEQ ID NO:2, however, one of skill in the art will recognize that depending upon the enzyme used, the expression system used and/or the conditions under which proteolytic cleavage of the polypeptide takes place, the cleavage site may vary from 1 to 3 amino acid in either direction of amino acid number 31 of SEQ ID NO:2.
  • polypeptide comprising SEQ ID NO:4 is typically cleaved following amino acid number 28 of SEQ ID NO:4, however, one of skill in the art will recognize that depending upon the enzyme used, the expression system used and/or the conditions under which proteolytic cleavage of the polypeptide takes place, the cleavage site may vary from 1 to 3 amino acid in either direction of amino acid number 31 of SEQ ID NO:4.
  • the disclosure also provides polynucleotides encoding the polypeptides of the disclosure.
  • the disclosure provides SEQ ID NO:1 and 3, which encode the polypeptides of SEQ ID NO:2 and 4.
  • hogocidin peptide refers to the mature form of hogocidins comprising a chain of amino acids that is about 30 to about 50 amino acids in length and comprises a sequence as set forth in SEQ ID NO:2 or 4 or post-translationally modified versions thereof:
  • SEQ ID NO:2 (from aa 32 to aa 61)—KCSWWNASCHLGNNGKICTVSHECAAGCNL
  • SEQ ID NO:4 (from aa 29 to aa 66)—ATPTITTSSATCGGIIVAASAAQCPTLACSSRCGKRKK.
  • the method provides hogocidin derivatives comprising (a) peptides that are at least 90% identical to a hogocidin peptide of SEQ ID NO:2 or 4 and having antimicrobial activity; (b) mature forms of (a) that have been post-translationally processed; (c) fragments of hogocidin peptides that are about 15-40 amino acids in length and have antimicrobial activity; (d) fusion proteins comprising (a)-(c) above and having antimicrobial activity; (e) peptides comprising any of (a), (b), (c) or (d) wherein one or more amino acids comprise a D-amino acid and the peptide has antimicrobial activity; and (f) retroinverso peptides of any of the foregoing and having antimicrobial peptides.
  • the method provides hogocidin derivatives comprising lanthionine or methyllanthionine residues, or hogocidin derivatives modified such that they contain lanthionine or methyllanthionine residues. It is not necessary that the analog, derivative, variation, or variant have activity identical to the activity of the hogocidin peptide from which the analog, derivative, conservative variation, or variant is derived so long as it has some antimicrobial activity.
  • the disclosure provides a hogocidin polypeptide comprising at least one conservative amino acid difference compared to polypeptide of SEQ ID NO:2 or 4.
  • the disclosure also provides a polypeptide comprising a sequence of SEQ ID NO:55 at the N-terminal end and wherein the polypeptide has antimicrobial activity and observed molecular weight was 3484.90 (m/z).
  • the polypeptide is produced by S. epidermidis A11.
  • compositions comprising a pharmaceutically acceptable excipient and comprising a substantially pure hogocidin peptide or derivative.
  • compositions comprising a probiotic formulation which includes one or more hogocidin- or firmocidin-producing bacterial strains.
  • purified refers to a peptide that is substantially free of other proteins, lipids, and polynucleotides (e.g., cellular components with which an in vivo produced peptide would naturally be associated). Typically, the peptide is at least 70%, 80%, or most commonly 90% pure by weight. As described more fully below, the composition can further comprise a cathelicidin peptide or derivative thereof.
  • a “variant” is an antimicrobial peptide (e.g., a hogocidin peptide of the disclosure) that is an altered form of a referenced antimicrobial peptide.
  • the term “variant” includes an antimicrobial peptide produced by the method disclosed herein in which at least one amino acid (e.g., from about 1 to 10 amino acids) of a reference peptide is substituted with another amino acid.
  • the term “reference” peptide means any of the antimicrobial peptides of the disclosure (e.g., a polypeptide consisting of SEQ ID NO:2 and 4 or a mature form thereof), from which a variant, derivative, analog, or conservative variation is derived.
  • derivative is a hybrid peptide that includes at least a portion of each of two antimicrobial hogocidin peptides.
  • Derivatives can be produced by adding one or a few (e.g., 1 to 5) amino acids to an antimicrobial peptide without completely inhibiting the antimicrobial activity of the peptide.
  • C-terminal derivatives e.g., C-terminal methyl esters, can be produced and are encompassed by the disclosure.
  • the disclosure also includes peptides that are conservative variations of those peptides as exemplified herein.
  • conservative variation denotes a polypeptide in which at least one amino acid is replaced by another, biologically, chemically, or structurally similar residue.
  • Examples of conservative variations include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine, alanine, cysteine, glycine, phenylalanine, proline, tryptophan, tyrosine, norleucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like.
  • Neutral hydrophilic amino acids that can be substituted for one another include asparagine, glutamine, serine and threonine.
  • Structurally conservative variations include the substitution of alanine for serine (and vice versa), isoleucine for threonine (and vice versa), arginine for lysine (and vice versa), and the replacement of any of tyrosine, phenylalanine, tryptophan, and histidine for any other member of that group.
  • the term “conservative variation” also encompasses a peptide having a substituted amino acid in place of an unsubstituted parent amino acid; typically, antibodies raised to the substituted polypeptide also specifically bind the unsubstituted polypeptide.
  • SH-lantibiotic refers to a compound comprising a post-translationally modified peptide produced by S. hominis which optionally contains one or more lanthionine or methyllanthionine moieties, and shows antimicrobial activity against one or more non- S. hominis species.
  • SH-antimicrobial refers to a compound comprising a non-lantibiotic compound produced or secreted by S. hominis , which may optionally comprise a non-lantibiotic peptide, and which shows antimicrobial activity against one or more non- S. hominis species.
  • SE-lantibiotic refers to a compound comprising a post-translationally modified peptide produced by S. epidermidis which optionally contains one or more lanthionine or methyllanthionine moieties, and shows antimicrobial activity against one or more non- S. epidermidis species.
  • the peptide comprises a sequence of SEQ ID NO:55.
  • SE-antimicrobial refers to a compound comprising a non-lantibiotic compound produced or secreted by S. epidermidis , which may optionally comprise a non-lantibiotic peptide, and which shows antimicrobial activity against one or more non- S. epidermidis species.
  • Hogocidin peptide variants of the disclosure can be identified by screening a large collection, or library, of random peptides or peptides of interest using, for example, one of a number of animal models such as CRAMP knockout mice that display increased susceptibility to skin infections.
  • Hogocidin peptide variants can be, for example, a population of peptides related in amino acid sequence to SEQ ID NO:2 and 4 by having various substitutions based upon such sequences.
  • Peptide libraries include, for example, tagged chemical libraries comprising peptides and peptidomimetic molecules. Peptide libraries also comprise those generated by phage display technology. Phage display technology includes the expression of peptide molecules on the surface of phage as well as other methodologies by which a protein ligand is or can be associated with the nucleic acid, which encodes it. Methods for the production of phage display libraries, including vectors and methods of diversifying the population of peptides, which are expressed, are known in the art (see, for example, Smith and Scott, Methods Enzymol. 217:228 257 (1993); Scott and Smith, Science 249:386 390 (1990); and Huse, WO 91/07141 and WO 91/07149).
  • a phage display library from which the displayed peptides can be cleaved and assayed for antibacterial activity. If desired, a population of peptides can be assayed for activity, and an active population can be subdivided and the assay repeated in order to isolate an active peptide from the population.
  • Other methods for producing peptides useful in the disclosure include, for example, rational design and mutagenesis based on the amino acid sequences of a hogocidin peptide as set forth in SEQ ID NO:2 or 4, for example.
  • a hogocidin peptide variant can be a peptide mimetic, which is a non-amino acid chemical structure that mimics the structure of, for example, a hogocidin peptide of SEQ ID NO:2 or 4 (or a mature form thereof) yet retains antimicrobial/antibacterial activity.
  • a mimetic generally is characterized as exhibiting similar physical characteristics such as size, charge or hydrophobicity in the same spatial arrangement found in the hogocidin peptide counterpart.
  • a specific example of a peptide mimetic is a compound in which the amide bond between one or more of the amino acids is replaced, for example, by a carbon-carbon bond or other bond well known in the art (see, for example, Sawyer, Peptide Based Drug Design, ACS, Washington (1995)).
  • amino acids of a hogocidin peptide, variant or peptidomimetic of the disclosure are selected from the twenty naturally occurring amino acids, including, unless stated otherwise, L-amino acids and D-amino acids.
  • D-amino acids are particularly useful for increasing the life of a protein or peptide.
  • Polypeptides incorporating D-amino acids are resistant to proteolytic digestion.
  • amino acid also refers to compounds such as chemically modified amino acids including amino acid analogs, naturally occurring amino acids that are not usually incorporated into proteins such as norleucine, and chemically synthesized compounds having properties known in the art to be characteristic of an amino acid, provided that the compound can be substituted within a peptide such that it retains its biological activity.
  • glutamine can be an amino acid analog of asparagine, provided that it can be substituted within an active fragment of a hogocidin peptide, variant and the like such that it retains its antimicrobial/antibacterial activity.
  • amino acids and amino acids analogs are listed in Gross and Meienhofer, The Peptides: Analysis, Synthesis, Biology, Academic Press, Inc., New York (1983).
  • An amino acid also can be an amino acid mimetic, which is a structure that exhibits substantially the same spatial arrangement of functional groups as an amino acid but does not necessarily have both the “-amino” and “-carboxyl” groups characteristic of an amino acid.
  • Polypeptides and peptides of the disclosure can be synthesized by commonly used methods such as those that include t-BOC or FMOC protection of alpha-amino groups. Both methods involve stepwise synthesis in which a single amino acid is added at each step starting from the C terminus of the polypeptide or peptide (See, Coligan, et al., Current Protocols in Immunology, Wiley Interscience, 1991, Unit 9). Polypeptide and peptides of the disclosure can also be synthesized by the well-known solid phase peptide synthesis methods such as those described by Merrifield, J. Am. Chem. Soc., 85:2149, 1962) and Stewart and Young, Solid Phase Peptides Synthesis, Freeman, San Francisco, 1969, pp. 27 62). If desired, the peptides can be quantitated by the solid phase Edman degradation.
  • a hogocidin peptide i.e., the mature form of SEQ ID NO:2 or 4 can be generated specifically without the need for post-translational processing.
  • the disclosure also includes isolated polynucleotides (e.g., DNA, cDNA, or RNA) encoding the polypeptide and peptides of the disclosure. Included are polynucleotides that encode analogs, mutants, conservative variations, and variants of the polypeptides and peptides described herein.
  • isolated refers to a polynucleotide that is substantially free of proteins, lipids, and other polynucleotides with which an in vivo-produced polynucleotides naturally associated. Typically, the polynucleotide is at least 70%, 80%, or 90% isolated from other matter, and conventional methods for synthesizing polynucleotides in vitro can be used in lieu of in vivo methods.
  • polynucleotide refers to a polymer of deoxyribonucleotides or ribonucleotides, in the form of a separate fragment or as a component of a larger genetic construct (e.g., by operably linking a promoter to a polynucleotide encoding a peptide of the disclosure).
  • Numerous genetic constructs e.g., plasmids and other expression vectors
  • prokaryotic or eukaryotic e.g., yeast, insect, or mammalian
  • polynucleotides of the disclosure can readily be used in conventional molecular biology methods to produce the peptides of the disclosure.
  • DNA encoding the hogocidin peptides, derivatives of variants thereof of the disclosure can be inserted into an “expression vector.”
  • expression vector refers to a genetic construct such as a plasmid, virus or other vehicle known in the art that can be engineered to contain a polynucleotide encoding a polypeptide of the disclosure.
  • Such expression vectors are typically plasmids that contain a promoter sequence that facilitates transcription of the inserted genetic sequence in a host cell.
  • the expression vector typically contains an origin of replication, and a promoter, as well as genes that allow phenotypic selection of the transformed cells (e.g., an antibiotic resistance gene).
  • Various promoters, including inducible and constitutive promoters can be utilized in the disclosure.
  • the expression vector contains a replicon site and control sequences that are derived from a species compatible with the host cell.
  • Transformation or transfection of a host cell with a polynucleotide of the disclosure can be carried out using conventional techniques well known to those skilled in the art.
  • competent cells that are capable of DNA uptake can be prepared using the CaCl 2 , MgCl 2 or RbCl methods known in the art.
  • physical means, such as electroporation or microinjection can be used. Electroporation allows transfer of a polynucleotide into a cell by high voltage electric impulse.
  • polynucleotides can be introduced into host cells by protoplast fusion, using methods well known in the art. Suitable methods for transforming eukaryotic cells, such as electroporation and lipofection, also are known.
  • “Host cells” encompassed by of the disclosure are any cells in which the polynucleotides of the disclosure can be used to express the hogocidin peptides, derivatives or variants of the disclosure.
  • the term also includes any progeny of a host cell.
  • Host cells which are useful, include bacterial cells, fungal cells (e.g., yeast cells), plant cells and animal cells.
  • host cells can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
  • Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology (1986)).
  • fungal cells such as yeast
  • insect cells such as Drosophila S2 and Spodoptera Sf9
  • animal cells such as CHO, COS or Bowes melanoma
  • plant cells and the like.
  • the selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.
  • a host cell can comprise a bacterial cell present in a normal bacterial flora of the skin that has been engineered to express or over express a hogocidin peptide or other antimicrobial peptide of the disclosure. These engineered bacterial cells can then be used as a probiotic such that they are applied to skin.
  • Host cells can be eukaryotic host cells (e.g., mammalian cells).
  • the host cells are mammalian production cells adapted to grow in cell culture. Examples of such cells commonly used in the industry are CHO, VERO, BHK, HeLa, CV1 (including Cos; Cos-7), MDCK, 293, 3T3, C127, myeloma cell lines (especially murine), PC12 and W138 cells.
  • Chinese hamster ovary (CHO) cells are widely used for the production of several complex recombinant proteins, e.g. cytokines, clotting factors, and antibodies (Brasel et al., Blood 88:2004 2012 (1996); Kaufman et al., J.
  • DHFR dihydrofolate reductase
  • the dihydrofolate reductase (DHFR)-deficient mutant cell lines are the CHO host cell lines commonly used because the efficient DHFR selectable and amplifiable gene expression system allows high level recombinant protein expression in these cells (Kaufman, Meth Enzymol 185:527 566 (1990)). In addition, these cells are easy to manipulate as adherent or suspension cultures and exhibit relatively good genetic stability. CHO cells and recombinant proteins expressed in them have been extensively characterized and have been approved for use in clinical manufacturing by regulatory agencies.
  • Polynucleotides encoding the polypeptide and peptides of the disclosure can be isolated from a cell (e.g., a cultured cell), or they can be produced in vitro.
  • a DNA sequence encoding a hogocidin peptide of interest can be obtained by: 1) isolation of a double-stranded DNA sequence from genomic DNA; 2) chemical manufacture of a polynucleotide such that it encodes the hogocidin peptide of interest; or 3) in vitro synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a donor cell (i.e., to produce cDNA).
  • any of various art-known methods for protein purification can be used to isolate the peptides of the disclosure.
  • preparative chromatographic separations and immunological separations such as those employing monoclonal or polyclonal antibodies
  • Carrier peptides can facilitate isolation of fusion proteins that include the peptides of the disclosure.
  • Purification tags can be operably linked to a hogocidin peptide of the disclosure.
  • GST glutathione-S-transferase
  • purification can be accomplished in a single step using an IgG-sepharose affinity column.
  • the pOprF-peptide which is the N-terminal half of the P. aeruginosa outer membrane protein F, can readily be purified because it is the prominent protein species in outer membrane preparations.
  • the fusion peptides can be purified using reagents that are specifically reactive with (e.g., specifically bind) the hogocidin peptide of the fusion peptide.
  • monoclonal or polyclonal antibodies that specifically bind the hogocidin peptide can be used in conventional purification methods. Techniques for producing such antibodies are well known in the art.
  • a fusion construct comprising a polypeptide linked to a hogocidin peptide of the disclosure can be linked at either the amino or carboxy terminus of the peptide.
  • the polypeptide that is linked to the hogocidin peptide is sufficiently anionic such that the hogocidin peptide has a net charge that is neutral or negative.
  • the anionic polypeptide can correspond in sequence to a naturally occurring protein or can be entirely artificial in design.
  • the polypeptide linked to a hogocidin peptide (the “carrier polypeptide”) may help stabilize the hogocidin peptide and protect it from proteases, although the carrier polypeptide need not be shown to serve such a purpose.
  • the carrier polypeptide may facilitate transport of the fusion peptide.
  • carrier polypeptides that can be utilized include anionic pre-pro peptides and anionic outer membrane peptides.
  • carrier polypeptides include glutathione-S-transferase (GST), protein A of Staphylococcus aureus , two synthetic IgG-binding domains (ZZ) of protein A, outer membrane protein F of Pseudomonas aeruginosa , protein transduction domains and the like.
  • GST glutathione-S-transferase
  • ZZ two synthetic IgG-binding domains
  • outer membrane protein F of Pseudomonas aeruginosa protein transduction domains and the like.
  • the disclosure is not limited to the use of these polypeptides; others suitable carrier polypeptides are known to those skilled in the art.
  • a linker moiety comprising a protease cleavage site may be operably linked to a hogocidin peptide or variant of the disclosure.
  • the linker may be operable between to domains of a fusion protein (e.g., a fusion protein comprising a hogocidin peptide and a carrier polypeptide).
  • a fusion protein e.g., a fusion protein comprising a hogocidin peptide and a carrier polypeptide.
  • the linker moiety can include the recognition sequence within flexible spacer amino acid sequences, such as GGGGS (SEQ ID NO: 6).
  • a linker moiety including a cleavage recognition sequence for Adenovirus endopeptidase could have the sequence GGGGGGSMFGGAKKRSGGGGGG (SEQ ID NO: 7).
  • the spacer DNA sequence can encode a protein recognition site for cleavage of the carrier polypeptide from the hogocidin peptide.
  • spacer DNA sequences include, but are not limited to, protease cleavage sequences, such as that for Factor Xa protease, the methionine, tryptophan and glutamic acid codon sequences, and the pre-pro defensin sequence.
  • Factor Xa is used for proteolytic cleavage at the Factor Xa protease cleavage sequence, while chemical cleavage by cyanogen bromide treatment releases the peptide at methionine or related residues.
  • the fused product can be cleaved by insertion of a codon for tryptophan (cleavable by o-iodosobenzoic acid) or glutamic acid (cleavable by Staphylococcus protease). Insertion of such spacer DNA sequences is not a requirement for the production of functional hogocidin peptides, such sequences can enhance the stability of the fusion peptide.
  • the pre-pro defensin sequence is negatively charged, so accordingly, it is envisioned within the disclosure that other DNA sequences encoding negatively charged peptides also can be used as spacer DNA sequences to stabilize the fusion peptide.
  • the disclosure also provides a method for inhibiting the growth of a bacterium by contacting the bacterium with an inhibiting effective amount of a peptide of the disclosure.
  • the term “contacting” refers to exposing the bacterium to the peptide so that the peptide can inhibit, kill, or lyse bacteria.
  • the disclosure also provides a method for inhibiting skin disease or disorder and/or bacterial infection comprising placing on or within a subject a probiotic formulation comprising bacteria which secrete a peptide or antimicrobial molecule such that the growth of the pathogen or undesirable microbe is inhibited or prevented.
  • Contacting of an organism with a hogocidin peptide of the disclosure can occur in vitro, for example, by adding the peptide to a bacterial culture to test for susceptibility of the bacteria to the peptide, or contacting a bacterially contaminated surface with the peptide.
  • contacting can occur in vivo, for example by administering the peptide to a subject afflicted with a bacterial infection or susceptible to infection.
  • contacting can occur by exposing the bacterium to a probiotic formulation comprising bacterial strains that produce the hogocidin peptide, or other peptide or non-peptide inhibitors of bacterial growth. In vivo contacting includes both parenteral as well as topical.
  • “Inhibiting” or “inhibiting effective amount” refers to the amount of peptide that is sufficient to cause, for example, a bacteriostatic or bactericidal effect.
  • Bacteria that can be affected by the peptides of the disclosure include both gram-negative and gram-positive bacteria.
  • bacteria that can be affected include Staphylococcus aureus, Streptococcus pyogenes (group A), Streptococcus sp. (viridans group), Streptococcus agalactiae (group B), S.
  • Streptococcus anaerobic species
  • Streptococcus pneumoniae and Enterococcus sp.
  • Gram-negative cocci such as, for example, Neisseria gonorrhoeae, Neisseria meningitidis , and Branhamella catarrhalis
  • Gram-positive bacilli such as Bacillus anthracis, Bacillus subtilis, P.
  • Infection with one or more of these bacteria can result in diseases such as bacteremia, pneumonia, meningitis, osteomyelitis, endocarditis, sinusitis, arthritis, urinary tract infections, tetanus, gangrene, colitis, acute gastroenteritis, impetigo, acne, acne posacue, wound infections, born infections, fascitis, bronchitis, and a variety of abscesses, nosocomial infections, and opportunistic infections.
  • Fungal organisms may also be affected by the hogocidin peptides of the disclosure and include dermatophytes (e.g., Microsporum canis and other Microsporum sp.; and Trichophyton sp. such as T.
  • yeasts e.g., Candida albicans, C. Tropicalis , or other Candida species
  • Saccharomyces cerevisiae Saccharomyces cerevisiae
  • Torulopsis glabrata Saccharomyces cerevisiae
  • Epidermophyton floccosum Malassezia furfur ( Pityropsporon orbiculare , or P.
  • the method for inhibiting the growth of bacteria can also include contacting the bacterium with the peptide in combination with one or more antibiotics.
  • a peptide(s) of the disclosure can be administered to any host, including a human or non-human animal, in an amount effective to inhibit growth of a bacterium, virus, or fungus.
  • the peptides are useful as antimicrobial agents, antiviral agents, and/or antifungal agents.
  • the bacterial strains that produce the peptides are useful as probiotic agents.
  • the peptide of the disclosure can be administered parenterally by injection or by gradual infusion over time.
  • the peptide can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, topically or transdermally.
  • a hogocidin peptide of the disclosure may be formulated for topical administration (e.g., as a lotion, cream, spray, gel, oil suspension, or ointment). Examples of formulations in the market place include topical lotions, creams, soaps, wipes, powders, devices like gauze pads to cover wounds, and the like.
  • liposomes may be formulated into liposomes to reduce toxicity or increase bioavailability or stability.
  • Other methods for delivery of the peptide include oral methods that entail encapsulation of the peptide in microspheres or proteinoids, aerosol delivery (e.g., to the lungs), or transdermal delivery (e.g., by iontophoresis or transdermal electroporation). Other methods of administration will be known to those skilled in the art.
  • Preparations for parenteral administration of a peptide of the disclosure include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters such as ethyl oleate.
  • aqueous carriers include water, saline, and buffered media, alcoholic/aqueous solutions, and emulsions or suspensions.
  • parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, and fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives such as, other antimicrobial, anti-oxidants, chelating agents, inert gases and the like also can be included.
  • the disclosure provides a method for inhibiting a topical bacterial or fungal-associated disorder by contacting or administering a therapeutically effective amount of a peptide or skin-probiotic of the disclosure to a subject who has, or is at risk of having, such a disorder.
  • inhibiting means preventing or ameliorating a sign or symptoms of a disorder (e.g., a rash, sore, and the like).
  • signs that can be ameliorated include an increase in a subject's blood level of TNF, fever, hypotension, neutropenia, leukopenia, thrombocytopenia, disseminated intravascular coagulation, adult respiratory distress syndrome, shock, and organ failure.
  • subjects who can be treated in the disclosure include human or animal subjects at risk for, or those suffering from, a toxemia, such as endotoxemia resulting from a gram-negative bacterial infection, venom poisoning, or hepatic failure.
  • a toxemia such as endotoxemia resulting from a gram-negative bacterial infection, venom poisoning, or hepatic failure.
  • Other examples include subjects having a dermatitis as well as those having skin infections such as mastitis and especially bovine mastits, or injuries subject to infection with gram-positive or gram-negative bacteria or a fungus.
  • candidate patients include those suffering from infection by E. coli, Hemophilus influenza B, Neisseria meningitides , staphylococci, or pneumococci.
  • a therapeutically effective amount as used herein for treatment of a subject afflicted with a disease or disorder means an amount of hogocidin peptide sufficient to ameliorate a sign or symptom of the disease or disorder.
  • a therapeutically effective amount can be measured as the amount sufficient to decrease a subject's symptoms of dermatitis or rash by measuring the frequency of severity of skin sores.
  • the subject is treated with an amount of hogocidin peptide sufficient to reduce a symptom of a disease or disorder by at least 50%, 90% or 100%.
  • the optimal dosage of the peptide will depend upon the disorder and factors such as the weight of the patient, the type of bacterial or fungal infection, the weight, sex, and degree of symptoms. Nonetheless, suitable dosages can readily be determined by one skilled in the art.
  • a suitable dosage is 0.5 to 40 mg peptide/kg body weight, e.g., 1 to 8 mg peptide/kg body weight.
  • a suitable therapy regime can combine administration of a peptide(s) or probiotic composition of the disclosure with one or more additional therapeutic agents (e.g., an inhibitor of TNF, an antibiotic, and the like).
  • the peptide(s), other therapeutic agents, and/or antibiotic(s) can be administered, simultaneously, but may also be administered sequentially.
  • Suitable antibiotics include aminoglycosides (e.g., gentamicin), beta-lactams (e.g., penicillins and cephalosporins), quinolones (e.g., ciprofloxacin), and novobiocin.
  • the antibiotic is administered in a bactericidal amount.
  • the peptide provides for a method of increasing antibiotic activity.
  • the hogocidin peptide and antibiotic are administered within 48 hours of each other (e.g., 2 to 8 hours, or may be administered simultaneously).
  • a “bactericidal amount” is an amount sufficient to achieve a bacteria-killing blood concentration in the subject receiving the treatment.
  • an “antibiotic,” as used herein, is a chemical substance that, in dilute solutions, inhibits the growth of, or kills microorganisms. Also encompassed by this term are synthetic antibiotics (e.g., analogs) known in the art.
  • the peptides of the disclosure can be used, for example, as preservatives or sterilants of materials susceptible to microbial or viral contamination.
  • the peptides can be used as preservatives in processed foods (e.g., to inhibit organisms such as Salmonella, Yersinia, Listeria and Shigella ).
  • the peptides can be used in combination with antibacterial food additives, such as lysozymes.
  • the peptides and/or probiotics of the disclosure also can be used as a topical agent, for example, to inhibit Pseudomonas or Streptococcus or kill odor-producing microbes (e.g., Micrococci).
  • the optimal amount of a hogocidin peptide of the disclosure for any given application can be readily determined by one of skill in the art.
  • the hogocidins and/or probiotics of the disclosure are also useful in promoting wound repair and tissue regeneration.
  • Matrix metalloproteinases are inflammatory enzymes that degrade proteins in various tissues.
  • MMPs proteases
  • compositions provided herein can be used concurrently with other antibacterial agents including sulfa drugs such as sulfamethizole, sulfisoxazole, sulfamonomethoxine, sulfamethizole, salazosulfapyridine, silver sulfadiazine and the like; quinoline antibacterial agents such as nalidixic acid, pipemidic acid trihydrate, enoxacin, norfloxacin, ofloxacin, tosufloxacin tosilate, ciprofloxacin hydrochloride, lomefloxacin hydrochloride, sparfloxacin, fleroxacin and the like; antiphthisics such as isoniazid, ethambutol (ethambutol hydrochloride), p-aminosalicylic acid (calcium p-aminosalicylate), pyrazinamide, ethionamide, protionamide, rifampicin, str
  • AMPs antimicrobial peptides
  • Cathelicidins are found in several mammalian species. Production of cathelicidins is induced in response to epithelial wounding or infectious challenge, or suppressed by the virulence mechanisms of certain bacterial pathogens, e.g., Shigella dysenteriae . Cathelicidin expression is also differentially effected in certain chronic inflammatory disorders. In psoriasis, cathelicidin levels are elevated and secondary infection is rare, whereas in atopic dermatitis cathelicidin expression is deficient and bacterial or viral superinfection is common.
  • a formulation, composition and method comprise both a hogocidin and cathelicidin.
  • a topical formulation e.g., a lotion, ointment or aerosol spray
  • Cathelicidin proteins are composed of two distinct domains: an N-terminal “cathelin-like” or “prosequence” domain and the C-terminal domain of the mature AMP.
  • the C-terminal domains of cathelicidins were among the earliest mammalian AMPs to show potent, rapid, and broad-spectrum killing activity.
  • the term “cathelin-like” derives from the similarity of the N-terminal sequence with that of cathelin, a 12 kDa protein isolated from porcine neutrophils that shares similarity with the cystatin superfamily of cysteine protease inhibitors.
  • Cathelicidins are expressed in neutrophils and myeloid bone marrow cells and most epithelial sources, and were the first AMPs discovered in mammalian skin due to their presence in wound fluid.
  • cathelicidins are synthesized as full length precursor and targeted to the secondary granules where they are stored.
  • the full-length cathelicidin protein is proteolytically processed to unleash the microbiocidal activity of the C-terminal peptide from the cathelin-like domain.
  • LL-37 The C-terminal 37 amino acids of human cathelicidin (LL-37) has been characterized.
  • LL-37 was originally referred to as FALL39, named for the first 4 N-terminal amino acids of this domain and the total number of residues (i.e., 39).
  • LL-37 is a peptide predicted to contain an amphipathic alpha helix and lacks cysteine, making it different from all other previously isolated human peptide antibiotics of the defensin family, each of which contain 3 disulfide bridges.
  • Full length human cathelicidin (sometimes referred to as full length LL-37) comprises the cathelin-like precursor protein and the C-terminal LL-37 peptide, thus comprising 170 amino acids (SEQ ID NO:5).
  • the polypeptide comprising SEQ ID NO:5 has a number of distinct domains.
  • a signal domain comprising a sequence as set forth from about 1 to about 29-31 of SEQ ID NO:5 is present.
  • the signal domain is typically cleaved following amino acid number 30 of SEQ ID NO:5, however, one of skill in the art will recognize that depending upon the enzyme used, the expression system used and/or the conditions under which proteolytic cleavage of the polypeptide takes place, the cleavage site may vary from 1 to 3 amino acid in either direction of amino acid number 30 of SEQ ID NO:5.
  • Another domain comprises the N-terminal domain, referred to as the cathelin-like domain.
  • the cathelin-like domain comprises from about amino acid 29 (e.g., 29-31) to about amino acid 128 (e.g., 128-131) of SEQ ID NO:5.
  • Yet another domain of SEQ ID NO:5 comprises the C-terminal domain referred to as LL-37.
  • the LL-37 domain comprises from about amino acid 128 (e.g., 128-134) to amino acid 170 of SEQ ID NO:5.
  • LL-37 comprises the amino acid sequence set forth in SEQ ID NO:5.
  • the mechanisms by which cationic human antimicrobial peptides kill bacteria and fungi are generally through binding of the peptide to the microbial cell membrane, after which the membrane's proton gradient and integrity are lost.
  • Vitamin D3 (or its analogs) with hogocidin (and in some embodiments in combination with a cathelicidin) can be administered systemically to treat systemic infections, in particular pneumonia, sepsis and TB. It may also be applied topically to treat infectious skin disorders. It may be used in combination therapy with antibiotics or to treat immunocompromised patients such as HIV positive individuals. In combination with immune stimulating approaches, it may therapeutically address cancer.
  • compositions and methods of the disclosure may also comprise treating disorders of skin dysbiosis by administration of an antimicrobial compound or an organism secreting an antimicrobial compound, or administration of a probiotic composition comprising organisms that support skin health.
  • the composition includes a second active agent (e.g., an antibiotic, vitamin D3, cathelicidin etc.).
  • the compositions described herein comprise a probiotic organism.
  • the probiotic organism is a bacterium.
  • the bacterium comprises a component of the normal skin flora.
  • the bacterium comprises a strain of Staphylococcus hominis .
  • the bacterium comprises a strain of Staphylococcus epidermidis .
  • the probiotic organism comprises a mixture of strains.
  • the mixture of strains comprises multiple strains of S. hominis .
  • the mixture of strains comprises multiple strains of S. epidermidis .
  • the mixture of strains comprises one or more strains of S.
  • the composition comprises one or more strains in addition to S. hominis and/or S. epidermidis .
  • the additional strain or strains comprise one or more strains from the genus Staphylococcus, Lactobacillus or Lactococcus .
  • specific formulations may comprise Staphylococcus hominis or Staphylococcus epidermidis , in particular, Staphylococcus hominis strain A9, Staphylococcus hominis strain C2, Staphylococcus hominis strain AMT2, Staphylococcus hominis strain AMT3, Staphylococcus hominis strain AMT4-C2, Staphylococcus hominis strain AMT4-G1, Staphylococcus hominis strain AMT4-D12, Staphylococcus epidermidis strain AMT1, Staphylococcus epidermidis strain SE-A11 , Staphylococcus epidermidis strain AMT5-C5, and/or Staphylococcus epidermidis strain AMT5-G6.
  • Such formulations typically comprise sufficient quantities of bacterial cells as to provide a final density of 10 3 -10 6 CFU/cm 2 when applied to the skin of a subject.
  • Such formulations may comprise concentrations of from about 10 4 to about 10 7 CFU/g, or alternatively, from 10 to about 10 5 CFU/g, or alternatively, from about 10 5 to about 10 9 CFU/g.
  • Such formulations may comprise multiple strains of S. hominis and/or S.
  • epidermidis may further comprise Lactococcus lactis, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus , and/or other such species or strains as are known in the art to form a part of the normal healthy cutaneous or mucosal flora.
  • S. hominis strains as described above comprise 100% of the bacterial cells in a formulation. In some further embodiments, S.
  • hominis comprises 90-100%, 85-95%, 70-80%, 75-85%, 60-70%, 65-75%, 50-60%, 55-65%, 40-50%, 45-55%, 30-40%, 35-45%, 20-30%, 25-35%, 10-20%, 15-20%, 1-10%, 5-15%, or less than 1% of the bacterial cells in a given formulation, wherein the remainder of the colony forming units are provided by S. epidermidis, Lactococcus lactis, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus , and/or other such strains as are known in the art to form a part of the normal healthy cutaneous or mucosal flora. In some embodiments, S.
  • epidermidis strains as described above comprise 100% of the bacterial cells in a formulation.
  • S. epidermidis comprises 90-100%, 85-95%, 70-80%, 75-85%, 60-70%, 65-75%, 50-60%, 55-65%, 40-50%, 45-55%, 30-40%, 35-45%, 20-30%, 25-35%, 10-20%, 15-20%, 1-10%, 5-15%, or less than 1% of the bacterial cells in a given formulation, wherein the remainder of the colony forming units are provided by S.
  • bacteria other than S. hominis or S. epidermidis comprise about 50% or less of the bacterial cells in the formulation. In some embodiments said bacteria comprise less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the bacterial cells within a given formulation. In some embodiments, bacteria other than S. hominis or S.
  • epidermidis may comprise Lactococcus lactis, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus , and/or other such species or strains as are known in the art to form a part of the normal healthy cutaneous or mucosal flora.
  • the formulations comprise about 60% S. hominis of the strains listed above and about 40% S. epidermidis of the strains listed above.
  • the formulations comprise about 50% S. hominis of the strains listed above and about 50% S. epidermidis of the strains listed above.
  • the formulations comprise about 40% S. hominis of the strains listed above and about 60% S.
  • the formulations comprise about 70% S. hominis of the strains listed above and about 30% S. epidermidis . In some embodiments, the formulations comprise about 30% S. hominis of the strains listed above and about 70% S. epidermidis of the strains listed above. In some embodiments, the formulations comprise about 80% S. hominis of the strains listed above and about 20% S. epidermidis of the strains listed above. In some embodiments, the formulations comprise about 20% S. hominis of the strains listed above and about 80% S. epidermidis of the strains listed above. In some embodiments, the formulations comprise about 90% S. hominis of the strains listed above and about 10% S.
  • the formulations comprise greater than about 90% S. hominis of the strains listed above and less than about 10% S. epidermidis of the strains listed above. In some embodiments, the formulations comprise less than about 10% S. hominis of the strains listed above and greater than about 90% S. epidermidis of the strains listed above.
  • an autologous transplant refers to the transplantation of bacterial strains from one site to another on the same subject or to the same site, regardless of whether the strains are cultured prior to administration or not.
  • the bacterial strains obtained from the subject are expanded in culture and then transplanted back to the subject.
  • an allogeneic transplant refers to the transplantation of bacterial strains from one subject to another subject, or to the administration to a subject of a composition comprising bacterial strains that were not collected from upon or within their own body.
  • Such collection can be carried out by swabbing, scraping, wiping, or cutting and removing tissue on which resides one of the bacterial strains as described herein; optionally growing and isolating single colonies from agar plates or otherwise using methods known in the art; optionally growing expanded cultures of the isolated bacteria or crude swabs, wipes, scrapes, tissue, or other isolate in liquid or solid culture according to methods known in the art; optionally harvesting bacteria from said expanded culture by centrifugation, filtration, gravity settling, scraping, or by other means known in the art; formulating the bacteria or the crude isolate with a thickener, carrier, or excipient; and contacting the subject in an area determined to be in need of the transplant, with said formulation.
  • a prebiotic compound comprises a polysaccharide, hydrolysate, salt, herbal extract, or any other compound sufficient to foster the growth of an associated probiotic strain when used in combination with that strain, such as yeast hydrolysate in concentrations of less than about 40% (w/w), microcrystalline cellulose in concentrations of less than about 10% (w/w), and/or sucrose in concentrations of less than about 10% (w/w).
  • yeast hydrolysate in concentrations of less than about 40% (w/w)
  • microcrystalline cellulose in concentrations of less than about 10% (w/w)
  • sucrose sucrose in concentrations of less than about 10% (w/w).
  • Other examples of prebiotics that may be adapted for use with cutaneous bacteria include inulin, glucooligosaccharides, isomaltooligosaccharides, lactosucrose, polydextrose, soybean oligosaccharides, and xylooligosaccharides, and those disclosed in Gibson, G.
  • the method comprises contacting a subject with a probiotic and/or prebiotic composition as described herein.
  • such contact comprises an autologous transplant.
  • such contact comprises an allogeneic transplant, wherein elements of the cutaneous or mucosal flora are transplanted to a first subject in need thereof from a second subject (the donor).
  • bacterial strains as disclosed above are identified and isolated from a second subject, amplified in an appropriate culture medium under such conditions as are known in the art to be conducive to bacterial growth, followed by harvest of the bacterial cells, mixing of the harvested cells at a predetermined concentration according to the disclosure with a predetermined formulation, and application of the mixture to the affected area of the first subject.
  • such composition comprises a standardized formulation, such as a formulation in which the concentrations of ingredients are fixed and are not varied from subject to subject.
  • the formulation is developed individually for each subject, based on criteria including but not limited to: the composition of the subject's own cutaneous or mucosal flora; the subject's disease state and treatment history; the nature and severity of the subject's condition; the nature and severity of concurrent cutaneous or mucosal infections; the presence of other antimicrobial compounds including systemic antibiotics within the subject's body; and other criteria such as are known to or would readily be apparent to those of skill in the art.
  • the composition comprises a cream, ointment, oil suspension or unguent wherein the probiotic bacteria as described above are incorporated within a moisturizer or emulsion such as those described below and in Nakatsuji, T. et al. (2016), Nature Medicine Submitted Manuscript No. NMED-A78395A, submitted Mar. 29, 2016.
  • the composition comprises a patch or poultice wherein the bacteria are combined with a suitable excipient and are incorporated within a fabric, gel matrix, or polymer sheet.
  • Suitable excipients and carriers for topical administration include thickeners, emulsifiers, fatty acids, polysaccharides, polyols, and polymers and copolymers, including, without limitation, alginate, microcrystalline cellulose, polylactic acid, polylactic-co-glycolic acid, petrolatum, and numerous others known in the art.
  • the composition comprises a bacterial culture medium, a conditioned bacterial culture medium, and/or a bacterial culture. In some embodiments, the composition comprises a filtrate or supernatant of a bacterial culture medium. In some embodiments, the composition comprises a lyophilized culture medium. In some embodiments, the composition comprises a lyophilized conditioned culture medium produced from a filtrate or supernatant of a bacterial culture medium.
  • the method as described herein comprises supporting the health of the skin of a subject.
  • the method comprises providing a treatment for skin dysbiosis and disorders derived therefrom.
  • the method comprises providing a treatment for bacterial infection of the skin.
  • the treatment comprises the steps of: identifying a subject with skin dysbiosis, bacterial infection, mastitis, burn or other wound, atopic dermatitis, psoriasis, or other chronic skin condition; and administering to the site of the condition in need of treatment the probiotic compositions as disclosed herein.
  • the probiotic compositions are re-applied at regularly timed intervals. In some embodiments, the probiotic compositions are reapplied every three days. In some embodiments, the probiotic compositions are reapplied every two days. In some embodiments, the probiotic compositions are reapplied every two days. In some embodiments, the probiotic compositions are reapplied daily. In some embodiments, the probiotic compositions are reapplied more than once per day. In some embodiments, the probiotic compositions are reapplied weekly. In some embodiments, the probiotic compositions are only applied a single time.
  • the method comprises providing a treatment for Staphylococcus aureus , including methicillin or oxacillin resistant S. aureus , infections.
  • the method comprises the steps of: diagnosing an S. aureus infection; and applying to the site of the infection the probiotic and/or prebiotic compositions as disclosed herein, wherein such compositions are capable of killing or inhibiting the growth of S. aureus , either by production of antimicrobial compounds, by competition for resources within the cutaneous or mucosal biota, or by other means. Determination of the appropriate mode of administration of a given formulation (ointment, gel, patch, etc.) can be done by one of ordinary skill in the art of treating skin infections.
  • the probiotic compositions are re-applied at regularly timed intervals (e.g., daily, every two days, every three days, weekly, etc.). It will be apparent to one of ordinary skill in the art that in other embodiments, similar or identical steps can be applied to provide a treatment for Pseudomonas aeruginosa infections or infections derived from bacteria of the genus Pseudomonas, Staphylococcus, Propionibacterium, Streptococcus , or Vibrio , or uncharacterized pathogens.
  • the method comprises providing a treatment for infections with unknown or uncharacterized pathogens. In some embodiments, the method comprises providing a treatment for polymicrobial infections.
  • the method comprises administering such treatment to a burn or wound. In some embodiments, the method comprises providing a treatment for a chronic skin condition. In some embodiments, the condition is atopic dermatitis, psoriasis, or other chronic skin condition.
  • Collection of live surface bacteria and bacterial DNA was done from a pre-measured area ( ⁇ 3 ⁇ 10 cm) of lesional skin on the antecubital fossa, and nonlesional skin of the upper arm at least 2 cm separated from the lesional site. Similar collections were obtained from non-atopic subjects at identical skin sites. Skin was rubbed with swabs pre-moistened with tryptic soy broth (TSB) for collecting live bacteria or with Tris-EDTA buffer for collecting bacterial DNA. Live bacteria samples were inoculated on a mannitol salt agar with egg yolk to distinguish coagulase negative staphylococcus (CONS).
  • TTB tryptic soy broth
  • Total genomic DNA was extracted with QIAamp DNA micro kit (Qiagen) and DNA abundance determined by quantitative real-time PCR (qPCR) with species- or genus-specific primers. No live Staphylococcus and Staphylococcus DNA were detected in 1 subject with atopic dermatitis out of 50 patients recruited. Therefore data are reported for 49 AD subjects.
  • rCFU relative CFU
  • epidermidis - CCAGAACAATGAATGGTTAAGG sequence sodA-R SEQ ID NO: 11
  • g-Staph-F TTTGGGCTACACACGTGCTACAATGGACAA Staphylococcus - SEQ ID NO: 12
  • genus specific g-Staph-R AACAACTTTATGGGATTTGCWTGA 16S sequence
  • SEQ ID NO: 13 Univ16S- AGAGTTTGGATCMTGGCTCAG Universal 27-F
  • SEQ ID NO: 14 sequence of Univ16S- AAGGAGGTGWTCCARCC bacterial 16S 1525-R (SEQ ID NO: 15) rRNA S. epidermidis - GATTCAGGAGCTGAACCAAGA S.
  • epidermidis X07840 epiA-F (SEQ ID NO: 16) epidermin S. epidermidis - TTGAAGCCCTGCCAATCTAA epiA-R (SEQ ID NO: 17) S. epidermidis - CTGATGAACTTGAACCTCAAACTG S. epidermidis L23967 pepA-F (SEQ ID NO: 18) PeP5 S. epidermidis - GACACTGTAAATAAACGCGTAGC pepA-R (SEQ ID NO: 19) S. epidermidis - GCAACTAGACAGGTATGTCCTAAA S. epidermidis Y14023 eciA-F (SEQ ID NO: 20) epicidin280 S.
  • epidermidis - CATCTAAGATTAAATGAGGGTGGTT eciA-R SEQ ID NO: 21
  • S. epidermidis - TAAGTCCGCAATCTGCTAGTG S. epidermidis U20348 elkA-F
  • epilancin K7 S. epidermidis - CAGTAATATTGCAACCGCATGT elkA-R
  • CoNS isolates Up to 84 individual colonies of CoNS isolates from each skin site were randomly picked and transferred to a 96-well cluster tube containing TSB. Each plate also received a non-antimicrobial strain of S. epidermidis (ATCC1457) as negative control, a known antimicrobial strain of Staphylococcus hominis (see below) as positive control, and blank wells without bacteria. CoNS were cultured at 37° C. overnight with shaking. Growth was evaluated by OD 600 . Bacteria were removed by centrifugation followed by sterile filtration with a 0.22 ⁇ m membrane. The antimicrobial activity released from each colony was evaluated by mixing with 1 ⁇ 10 4 colony-forming units (CFU) of S. aureus (ATCC35556).
  • CFU colony-forming units
  • Antimicrobial strains were defined as those that suppressed S. aureus growth after 22 hrs to less than 50% (I 50 ) of growth seen in negative controls. Insufficient CoNS colonies were grown from some of the subjects recruited. Therefore data are reported for 29 non-atopic subjects and 41 nonlesional and 40 lesional sites of atopic subjects. All CoNS isolates were stored frozen for species identification. Full-length 16S rRNA genes were amplified from 48 representative colonies with universal 16S primers, 27-F and 1525-R. Amplicons were sequenced from both ends by Sanger method.
  • Sterile conditioned media from a representative antimicrobial S. hominis strain isolated from a healthy subject was used to further identify molecules with antimicrobial activity on normal skin that were in low abundance on atopics.
  • Activity was precipitated by ammonium sulfate (70% saturation), dissolved in H 2 O and applied on a Sep-Pak cartridge (Waters Co). Active fractions were eluted with 30% acetonitrile in H 2 O and subjected to HiTrap® SP (GE Healthcare Life Sciences) separation and activity eluted at 125 mM NaCl.
  • HiTrap® SP GE Healthcare Life Sciences
  • Antimicrobial activity was purified from sterile conditioned media of a representative antimicrobial S. hominis strain isolated from a non-atopic subject.
  • the secondary structure of the purified active molecules was determined by MALDI-TOF/TOF, Edman terminal sequencing, and genome sequencing.
  • Mass spectra of HPLC-purified AMPs from S. hominis were recorded using a MALDI-TOF/TOF Bruker AutoflexTM Speed instrument (Bruker Daltonics) controlled by the flexcontrol software (Bruker Daltonics). Mass spectrometric analyses were performed in positive ion reflectron mode using cyano-4-hydroxycinnamic acid as a matrix (CHCA) 10 mg/mL (Sigma-Aldrich) dissolved in 50% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA). Full scan mass spectra were acquired in positive ion reflectron mode for mass range 1000-4000 m/z.
  • CHCA cyano-4-hydroxycinnamic acid as a matrix
  • ACN acetonitrile
  • TFA trifluoroacetic acid
  • Each mass spectrum is the result of 750 averaged laser shots with the laser intensity set around 65% of full laser intensity and a detector gain enhanced at 8 ⁇ 4 GS/s (as selected within the Bruker Flex Control software).
  • Each MS/MS spectrum is the result of 1000 averaged laser shots with the laser intensity set around 60% selected within the software and a detector gain enhanced at 10 ⁇ 4 GS/s. Resulting mass spectra were analyzed using flex analysis software (Bruker Daltonics). Spectra were calibrated to PepMix internal standard solutions.
  • the N-terminal amino acid sequence of purified Hogocidin- ⁇ was analyzed by 15 cycles of Edman degradation on Procise® 494HT Protein Sequence system (Applied Biosystems). A predicted mature form of Hogocidin- ⁇ is shown in FIG. 5A .
  • a core peptide with sequence ATPTITTSSATCGGIIVAASAAQCPTLACSSRCGKRKK (SEQ ID NO:4 from aa 29 to 66) cleaved from leader peptide with a GG cleavage site, common for type 2 lantibiotics.
  • Genomic DNA was purified using UltraClean® Microbial DNA Isolation kit (MO Bio).
  • Whole genome DNA sequencing libraries were constructed using the Nextera-XT DNA Sample Prep Kit (Illumina) following the vendor's protocol. The final library was sequenced by paired end sequencing (300 ⁇ 300) on an Illumina MiSeqTM. Sequenced reads were de novo assembled using SPAdes 2.5.1 with k-mers of lengths 21, 33, 55, 77, and 127 and the flag for “careful” turned on.
  • S. aureus ATCC35556 strain to test antimicrobial activity of purified fractions. Briefly, melted TSB agar (10 mL) was mixed with S. aureus (1 ⁇ 10 6 CFU) and poured in a 10 cm petri dish. Two to four ⁇ L of test samples was applied in a small well punched on the agar plate. Plates were incubated at 37° C. overnight to allow visible growth of bacteria. Antibacterial activity was indicated by the clear zone (no bacterial growth) around the well. Antimicrobial activity of Hogocidins was evaluated by incubating S.
  • Paired t-tests were used to compare lesional to non-lesional samples within atopic subjects and independent t-tests were used to compare non-atopic to atopic samples.
  • Longitudinal mixed models of frequency of antimicrobial CoNS and the ratio of live Staphylococcus to Staphylococcus DNA over time were also fit. Each model included lesion type, visit, and their interaction term as fixed effects, while a compound symmetry structure was used to account for correlation between samples obtained from the same subject at multiple time points.
  • Statistical analyses were performed using SAS (version 9.3) software.
  • N-terminal amino acid sequencing of the 3152.2 Da peptide was KCSWWNAA.
  • the full sequence of the 3547.7 Da peptide was obtained by genome-guided MALDI-TOF/TOF analysis ( FIG. 8 ). Alignment of mass and amino acid sequence to the genome sequence of this S. hominis strain revealed that these novel AMPs were encoded within the gene cluster of lanM, lanC and lanT homologs ( FIG. 9 ), and consistent with identities as lantibiotics.
  • AMPs were previously unknown, they were named Hogocidin- ⁇ (3152.2 Da) and - ⁇ (3547.7 Da) from the Japanese “Hogo” meaning “Protect.” These newly described AMPs were readily detectable by PCR in 50% of 14 non-atopic individuals.
  • the predicted secondary structures of mature Hogocidin- ⁇ and Hogocidin- ⁇ are shown in FIG. 5A .
  • the minimal bactericidal concentration (>99.9% killing) of purified Hogocidin- ⁇ and - ⁇ against S. aureus was 0.625 ⁇ M and 1.25 ⁇ M, respectively ( FIG. 5B ), an activity more potent than conventional AMPs produced on human skin.
  • lipid composition of whole bacterial cells (predominantly the cell membranes), which can be represented by the relative abundance of fatty acid methyl esters present in a saponified and methylated sample of bacterial cell extracts, is very nearly unique to each strain, the identified strains were subjected to Fatty Acid Methyl Ester (FAME) analysis.
  • FAME Fatty Acid Methyl Ester
  • Bacterial strains were cultured and harvested according to standard techniques. Cells were subjected to saponification and methylation before being extracted into the mobile phase solvent for gas chromatography. Samples were loaded and run according to the instrument manufacturer's instructions. The resulting chromatograms are shown in FIGS. 11 through 19 .
  • Frozen pig skin sheet was obtained from Loretta Tomlin Animal Technologies (Livermore, Calif.) and sanitized by surgical brush with 3% chloroxylenol. The skin sheet was cut into 2.5 cm ⁇ 2.5 cm and rinsed with sterile PBS more than 20 times to remove chloroxylenol residue.
  • Back skin of C57BL6 female, 6 week-old mice that were randomly selected was shaved, treated with depilatory cream and rinsed with water at least 24 hrs before bacteria application. The shaved skin was cleaned with alcohol swab twice to remove originally colonized bacteria. All experiments involving live animal work were in accordance with the approval of the Institutional Animal Care and Use Guidelines.
  • S. aureus (ATCC35556) (1 ⁇ 10 5 CFU/cm 2 ) were epicutaneously challenged on the pig skin (2.5 ⁇ 2.5 cm) or dorsal skin of mice (2 ⁇ 2 cm).
  • hominis C4, C5 and C6 (1 ⁇ 10 5 CFU/10 ⁇ L), or vehicle were subsequently applied on the surface of pig skin or mouse dorsal skin for 20 hrs ( FIGS. 20A and 20B ).
  • Purified lantibiotic (0.5 nmol), conditioned media of S. hominis A9 (50 ⁇ L) were applied to the surface of sanitized pig skin.
  • Pig skin was incubated at 30° C. in a 6-well plate.
  • Live bacteria were harvested with a Catch-All Swab pre-wetted with TSB from the skin surface as described above. Bacteria were suspended by vortex swab head vigorously in 1 mL TSB.
  • AMT autologous microbiome transplant
  • FDA US Food and Drug Administration
  • IND investigational new drug application
  • AD patients who are S. aureus carriers on the lesional sites of both antecubital fossa were screened.
  • skin bacteria were obtained by swabbing from nonlesional skin of upper arm of AD patient to screen CoNS strain producing antimicrobial activity against S. aureus .
  • Species of antimicrobial CoNS isolates were identified by Sanger sequencing of the full-length 16S rRNA gene.
  • Glycerol stocks of CoNS isolates were stored at ⁇ 80° C.
  • each CoNS strain was individually expanded in TSB overnight. Each CoNS strain was formulated at 1 ⁇ 10 7 CFU/g in skin moisturizer which was confirmed not to affect bacteria viability. Only a single S. epidermidis or S. hominis strain with antimicrobial activity was isolated from 3 patients. In these cases, a single strain of CoNS was formulated. Three and 2 antimicrobial S. hominis or S. epidermidis strains were isolated from 2 AD patients ( FIG. 20D ). In these cases, an equal CFU of each CoNS was formulated at the total concentration of 10 7 CFU/g. At the second visit, involved area was measured and the baseline CFU of live S.
  • aureus on lesional sites of both forearm was quantified as described above.
  • One arm was treated with AMT formulation at 10 mg/cm 2 to get 1 ⁇ 10 5 CFU/cm 2 of CONS.
  • the other arm received an equal amount of moisturizer only. All treatment was conducted in double-blinded fashion and unblinded after all results were analyzed. Subjects avoided bathing, showering, exercising or applying any topical products to their arms, and wore a clean and long-sleeved shirt to avoid cross contamination of applied CoNS to the other arm until the next visit. At the third visit, S. aureus CFU in involved area was measured. Difference in S.
  • Sterile conditioned media from a representative antimicrobial S. epidermidis A11 strain was used to further identify molecules with antimicrobial activity on normal skin that were in low abundance on atopics. Activity was precipitated by ammonium sulfate (70% saturation), dissolved in H 2 O and applied on a Sep-Pak cartridge (Waters Co). Active fractions were eluted with 40% acetonitrile in H 2 O and subjected to HiTrap® SP (GE Healthcare Life Sciences) separation and activity eluted at 500 mM NaCl.
  • HiTrap® SP GE Healthcare Life Sciences
  • Antimicrobial activity was purified from sterile conditioned media of a representative antimicrobial S. epidermidis A11 strain isolated from a non-atopic subject. The characteristics of the purified active molecule was determined by MALDI-TOF/TOF and Edman terminal sequencing.
  • Mass spectra of HPLC-purified AMPs from S. epidermidis A11 were recorded using a MALDI-TOF/TOF Bruker AutoflexTM Speed instrument (Bruker Daltonics) controlled by the flexcontrol software (Bruker Daltonics). Mass spectrometric analyses were performed in positive ion reflectron mode using cyano-4-hydroxycinnamic acid as a matrix (CHCA) 10 mg/mL (Sigma-Aldrich) dissolved in 50% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA). Full scan mass spectra were acquired in positive ion reflectron mode for mass range 1000-6000 m/z.
  • CHCA cyano-4-hydroxycinnamic acid as a matrix
  • ACN acetonitrile
  • TFA trifluoroacetic acid
  • Each mass spectrum is the result of 750 averaged laser shots with the laser intensity set around 65% of full laser intensity and a detector gain enhanced at 8 ⁇ 4 GS/s (as selected within the Bruker Flex Control software). Resulting mass spectra were analyzed using flex analysis software (Bruker Daltonics). Spectra were calibrated to PepMix internal standard solutions.
  • the N-terminal amino acid sequence of purified was analyzed by 15 cycles of Edman degradation on Procise® 494HT Protein Sequence system (Applied Biosystems).
  • the N-terminal sequence is provided in SEQ ID NO:55.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US15/570,272 2015-05-05 2016-05-05 Antimicrobial therapy Abandoned US20180289751A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/570,272 US20180289751A1 (en) 2015-05-05 2016-05-05 Antimicrobial therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562157248P 2015-05-05 2015-05-05
US201662300274P 2016-02-26 2016-02-26
US15/570,272 US20180289751A1 (en) 2015-05-05 2016-05-05 Antimicrobial therapy
PCT/US2016/031067 WO2016179440A2 (en) 2015-05-05 2016-05-05 Antimicrobial therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/031067 A-371-Of-International WO2016179440A2 (en) 2015-05-05 2016-05-05 Antimicrobial therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/653,911 Division US10980848B2 (en) 2015-05-05 2019-10-15 Antimicrobial therapy

Publications (1)

Publication Number Publication Date
US20180289751A1 true US20180289751A1 (en) 2018-10-11

Family

ID=57218441

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/570,272 Abandoned US20180289751A1 (en) 2015-05-05 2016-05-05 Antimicrobial therapy
US16/653,911 Active US10980848B2 (en) 2015-05-05 2019-10-15 Antimicrobial therapy
US17/220,308 Pending US20210228652A1 (en) 2015-05-05 2021-04-01 Antimicrobial therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/653,911 Active US10980848B2 (en) 2015-05-05 2019-10-15 Antimicrobial therapy
US17/220,308 Pending US20210228652A1 (en) 2015-05-05 2021-04-01 Antimicrobial therapy

Country Status (11)

Country Link
US (3) US20180289751A1 (ko)
EP (1) EP3291824A4 (ko)
JP (3) JP6981878B2 (ko)
KR (2) KR102419616B1 (ko)
CN (2) CN107735098B (ko)
AU (2) AU2016256882B2 (ko)
BR (1) BR112017023707B1 (ko)
CA (1) CA2984890C (ko)
HK (1) HK1250639A1 (ko)
MX (1) MX2017014020A (ko)
WO (1) WO2016179440A2 (ko)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131997A1 (en) 2018-12-21 2020-06-25 Matrisys Bioscience, Inc. Topical formulations for the delivery of microbially derived materials
EP3692980A1 (en) 2019-02-11 2020-08-12 BiomCare s.r.o. Combined multistage microbial preparations and method of their application
WO2021154954A1 (en) * 2020-01-29 2021-08-05 Etheim Biotics, Llc Compositions and methods for treating biofilms, infections and periodontitis
CN113730648A (zh) * 2021-09-06 2021-12-03 温州瑞司特生物科技有限公司 结合表皮葡萄球菌的水凝胶及其在治疗创面中的应用
EP4311537A1 (en) * 2022-07-26 2024-01-31 Beiersdorf AG Novel skin care composition for treating atopic dermatitis
EP4096699A4 (en) * 2020-01-29 2024-03-13 Jackson Lab BACTERIAL ADDITIVES

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735098B (zh) * 2015-05-05 2022-07-29 加利福尼亚大学董事会 抗微生物疗法
CN105796624A (zh) * 2016-05-11 2016-07-27 西安膳方医药科技有限公司 一种改善生物体表健康的方法
KR20200089649A (ko) * 2017-08-08 2020-07-27 유니베르시떼 드 베르사이유 쎙 깡뗑 앙 이브렝 인공적인 세균 집락형성을 사용하는 스타필로코커스 아우레우스의 예방을 위한 약학 조성물 및 방법
RU2699540C2 (ru) * 2017-08-17 2019-09-06 Павел Павлович Несмиянов Композиция, содержащая пробиотические бактерии или их компоненты, и способ ее применения в лечении иммунных заболеваний кожи
AU2019203692A1 (en) * 2018-08-30 2020-03-19 Johnson & Johnson Consumer Inc. Topical composition containing glycerin and yeast extract
MX2021003006A (es) 2018-09-13 2021-05-27 Univ California Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
CN113365646A (zh) * 2019-01-15 2021-09-07 诺维信公司 用于调节真皮和真皮下特性的基于孢子的益生菌组合物
US20220023355A1 (en) * 2019-02-04 2022-01-27 Riken Pharmaceutical composition for prevention, amelioration, or treatment of skin disease
AU2020218748B2 (en) * 2019-02-05 2023-12-21 Biomedit, Llc A genetically modified lactobacillus and uses thereof
EP3705131A1 (en) * 2019-03-04 2020-09-09 University College Cork-National University of Ireland, Cork Lantibiotics and lantibiotic-producing bacteria
US20220143153A1 (en) * 2019-03-08 2022-05-12 The Regents Of The University Of California Compositions and methods for treating acne
JP2021001133A (ja) * 2019-06-21 2021-01-07 ポーラ化成工業株式会社 スタフィロコッカス・ホミニス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ｈｏｍｉｎｉｓ）を有効成分とする肌状態改善剤
DE102019007505A1 (de) * 2019-10-28 2021-04-29 Beiersdorf Ag Zusammensetzung mit probiotischen Bakterien und Licochalcon A
DE102019007507A1 (de) * 2019-10-28 2021-04-29 Beiersdorf Ag Zusammensetzung mit probiotischen Bakterien und Protektor-Stämmen
US20240058395A1 (en) * 2021-01-26 2024-02-22 The Regents Of The University Of California Antimicrobial therapy
EP4082545A1 (en) * 2021-04-27 2022-11-02 Diotheris Combination product and methods for preventing the emergence of antibiotic-resistant bacteria under antibiotic treatment
CZ309480B6 (cs) * 2021-09-30 2023-02-15 BiomServ s.r.o Přípravky na ochranu mikrobiomu kůže a sliznic proti patogenním mikrobům a virům
WO2023086883A1 (en) * 2021-11-11 2023-05-19 Concerto Biosciences, Inc. Microbial compositions for the treatment of skin diseases
WO2023119287A1 (en) * 2021-12-22 2023-06-29 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Nomadic bacteria and uses thereof
TW202408552A (zh) * 2022-05-16 2024-03-01 日商瑪路弘股份有限公司 白癬治療用組成物
CN117343856A (zh) * 2022-06-28 2024-01-05 上海菌济健康科技有限公司 具有促进毛发生长的人体共生菌及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925556A (en) * 1996-10-02 1999-07-20 Agency Of Industrial Science And Technology Method of degrading polylactic acid resin using staphylococcus hominis and staphylococcus epidermidis
WO2007114510A1 (en) * 2006-03-31 2007-10-11 Canon Kabushiki Kaisha Probe, probe set, probe-immobilized carrier, and genetic testing method
AU2007249792B2 (en) * 2006-05-12 2012-08-02 The Board Of Trustees Of The University Of Illinois Antimicrobial therapy for bacterial infections
US20080026999A1 (en) * 2006-07-28 2008-01-31 Van Der Donk Wilfred A Two-component bacillus lantibiotic and methods for producing and using the same
US20100166708A1 (en) 2007-02-20 2010-07-01 The Regents Of The University Of California Antimicrobial and anti-inflammatory therapies and compositions
US20090041727A1 (en) * 2007-08-08 2009-02-12 Conjugon, Inc. Compositions and Methods for Microbe Storage and Delivery
EP2556085A2 (en) * 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
US20130331384A1 (en) * 2011-02-15 2013-12-12 The Regents Of The University Of California Firmocidin, an antimicrobial molecule produced by staphylococcus epidermidis
US9333227B2 (en) * 2013-08-19 2016-05-10 Syngulon Sa. Controlled growth of microorganisms
CN107735098B (zh) * 2015-05-05 2022-07-29 加利福尼亚大学董事会 抗微生物疗法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Higaki et al., Distribution and antimicrobial susceptibility of coagulase-negative staphylococci from skin lesions. The J. Int. Med. Res., 1999, Vol. 27: 191-195 (Year: 1999) *
Kloos et al., Update on clinical significance of coagulase-negative staphylococci. Clin. Microbiol. Rev., 1994, Vol. 7(1): 117-140. (Year: 1994) *
Saponins, 2 pages, http://www.ecologicalsurfactants.com/saponin/, retrieved, 03/13/2014 (Year: 2014) *
Surfactants, 8 pages, http://www.rsc.org/chemistryworld/issues/2003/july/amphiphiles.asp/, retrieved 03/13/2014 (Year: 2014) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131997A1 (en) 2018-12-21 2020-06-25 Matrisys Bioscience, Inc. Topical formulations for the delivery of microbially derived materials
EP3692980A1 (en) 2019-02-11 2020-08-12 BiomCare s.r.o. Combined multistage microbial preparations and method of their application
WO2021154954A1 (en) * 2020-01-29 2021-08-05 Etheim Biotics, Llc Compositions and methods for treating biofilms, infections and periodontitis
EP4096699A4 (en) * 2020-01-29 2024-03-13 Jackson Lab BACTERIAL ADDITIVES
CN113730648A (zh) * 2021-09-06 2021-12-03 温州瑞司特生物科技有限公司 结合表皮葡萄球菌的水凝胶及其在治疗创面中的应用
EP4311537A1 (en) * 2022-07-26 2024-01-31 Beiersdorf AG Novel skin care composition for treating atopic dermatitis
WO2024023190A1 (en) * 2022-07-26 2024-02-01 Beiersdorf Ag Novel skin care composition for treating atopic dermatitis

Also Published As

Publication number Publication date
CA2984890A1 (en) 2016-11-10
WO2016179440A3 (en) 2017-02-09
AU2016256882B2 (en) 2022-06-02
BR112017023707B1 (pt) 2022-03-29
US20200246397A1 (en) 2020-08-06
BR112017023707A2 (pt) 2018-07-31
US20210228652A1 (en) 2021-07-29
HK1250639A1 (zh) 2019-01-11
US10980848B2 (en) 2021-04-20
KR20220101014A (ko) 2022-07-18
KR102624665B1 (ko) 2024-01-12
AU2016256882A1 (en) 2017-11-23
CA2984890C (en) 2023-04-11
JP2018515488A (ja) 2018-06-14
EP3291824A4 (en) 2019-01-23
WO2016179440A2 (en) 2016-11-10
KR20180002710A (ko) 2018-01-08
EP3291824A2 (en) 2018-03-14
JP2022028833A (ja) 2022-02-16
MX2017014020A (es) 2018-08-14
CN115715781A (zh) 2023-02-28
CN107735098A (zh) 2018-02-23
JP6981878B2 (ja) 2021-12-17
KR102419616B1 (ko) 2022-07-12
AU2022203288A1 (en) 2022-06-09
JP7348255B2 (ja) 2023-09-20
CN107735098B (zh) 2022-07-29
JP2023175748A (ja) 2023-12-12

Similar Documents

Publication Publication Date Title
US10980848B2 (en) Antimicrobial therapy
US20070037744A1 (en) Human cathelicidin antimicrobial peptides
Conlon et al. A family of brevinin-2 peptides with potent activity against Pseudomonas aeruginosa from the skin of the Hokkaido frog, Rana pirica
WO2013086003A1 (en) Antimicrobial agent, bacterial strain, biosynthesis, and methods of use
US20220064217A1 (en) Defensin fragments for use in therapy or prophylaxis
US20210283215A1 (en) Bacteriotherapy against proprionibacterium acnes for the treatment of acne
US20180186843A1 (en) New antimicrobial peptides, their variants and uses
JP2011509966A (ja) 抗菌組成物
JP2006519217A (ja) 抗菌剤
US20240058395A1 (en) Antimicrobial therapy
US11096985B2 (en) Antimicrobial peptides, their variants and uses
EP3423477B1 (en) New antimicrobial peptides, their variants and uses
US20160271220A1 (en) Compositions and methods for using and identifying antimicrobial agents
MX2014001998A (es) Uso de peptidos sinteticos como antibioticos contra mycobacterium tuberculosis y otras bacterias patogenas.

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA, SAN DIEGO;REEL/FRAME:047818/0584

Effective date: 20181204

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GALLO, RICHARD L.;NAKATSUJI, TERUAKI;REEL/FRAME:051760/0463

Effective date: 20150518